Gly-Gly-Phe-Gly
Based on 1 Customer Validation
Gly-Gly-Phe-Gly is a peptide spacer and can be applied to Doxorubicin (HY-15142A) (DXR) conjugates. Gly-Gly-Phe-Gly can be used as an ADC linker to synthesize ADCs, such as Puxitatug samrotecan (AZD 8205) (HY-171689).
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 200427-88-9
- Formula: C15H20N4O5
- Molecular Weight:336.34
-
Storage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Gly-Gly-Phe-Gly can be efficiently recognized and cleaved by proteases in tumor tissues, and the release rate of its associated DXR prodrug is relatively fast. It is an ideal fast-release type peptide linker[1].
Gly-Gly-Phe-Gly can be specifically cleaved in lysosomes and can be used as an ADC linker to construct ADCs. This peptide linker remains stable during systemic circulation, which helps to reduce systemic toxicity[2][3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 200427-88-9
-
Appearance Solid
-
Molecular Weight 336.34
-
Formula C15H20N4O5
-
Color White to off-white
-
Sequence Shortening
GGFG
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 100 mg/mL (297.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (74.33 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shiose Y, et al. Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates. Bioconjug Chem. 2009 Jan;20(1):60-70. [Content Brief]
[2]. Nakada T, et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett. 2016 Mar 15;26(6):1542-1545. [Content Brief]
[3]. Kinneer K, et al. Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clin Cancer Res. 2023 Mar 14;29(6):1086-1101. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.9732 mL | 14.8659 mL | 29.7318 mL | 74.3295 mL |
| 5 mM | 0.5946 mL | 2.9732 mL | 5.9464 mL | 14.8659 mL | |
| 10 mM | 0.2973 mL | 1.4866 mL | 2.9732 mL | 7.4330 mL | |
| 15 mM | 0.1982 mL | 0.9911 mL | 1.9821 mL | 4.9553 mL | |
| 20 mM | 0.1487 mL | 0.7433 mL | 1.4866 mL | 3.7165 mL | |
| 25 mM | 0.1189 mL | 0.5946 mL | 1.1893 mL | 2.9732 mL | |
| 30 mM | 0.0991 mL | 0.4955 mL | 0.9911 mL | 2.4777 mL | |
| 40 mM | 0.0743 mL | 0.3716 mL | 0.7433 mL | 1.8582 mL | |
| 50 mM | 0.0595 mL | 0.2973 mL | 0.5946 mL | 1.4866 mL | |
| 60 mM | 0.0496 mL | 0.2478 mL | 0.4955 mL | 1.2388 mL | |
| DMSO | 80 mM | 0.0372 mL | 0.1858 mL | 0.3716 mL | 0.9291 mL |
| 100 mM | 0.0297 mL | 0.1487 mL | 0.2973 mL | 0.7433 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Gly-Gly-Phe-Gly Related Classifications
HY-P3669 Related Classifications
Powered by Bioz